Healthcare: The Crazy Back-Story To Sarepta Therapeutics' Game-Changing Approval

<p>Hit or miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy.</p>